Recursion (RXRX) Director Dar Zavain Receives 4,902-Share Award

What Happened
Dar Zavain, a director of Recursion Pharmaceuticals, was issued 4,902 shares on April 1, 2026. The Form 4 reports the acquisition as an award/grant (transaction code A) at $0.00 per share (reported value $0), reflecting issuance as compensation rather than a market purchase.

Key Details

• Transaction date: 2026-04-01; reported as an award/grant (Code A).
• Price reported: $0.00 per share; total reported cash value: $0.
• Shares issued: 4,902.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: Shares issued pursuant to the Issuer's Outside Director Compensation Policy (F1).
• Filing date: 2026-04-02 — filed the day after the transaction (no late-filing indication given).

Context
This was a compensation grant to a non-employee director, a routine corporate practice to pay directors in equity. Such awards are standard and do not by themselves signal the director buying or selling based on market views.